Station X

Station X develops software for scientists and clinicians who work with human genomics data in either research or clinical settings.  Our mission is to deliver the next generation of personalized medicine applications.

About the name

In World War II, Station X was the code name for Bletchley Park, the Allies' top-secret center for deciphering enemy codes.  It was at Station X that Alan Turing (who many consider the father of computer science) and his team cracked the Enigma code.  Recruitment at Bletchley Park was also groundbreaking in its diversity - the cryptanalysts included linguists, chess champions, crossword experts, polyglots and mathematicians, selected from all sectors of society.  We named our company Station X because we believe that cracking the genetic code will also need a combination of computational power and smart people with diverse skills and backgrounds.



Our team has a broad background in genomics and bioinformatics, as well as experience managing diverse teams to develop profitable genomic information products.


Chief Executive Officer, Founder

Chief Scientific Officer, Founder


Vice President, Products & Services


Vice President, Commercial Operations


Lead Software Developer


Director of Software Engineering


Board & Advisors

Richard D Goold, PhD
Chief Executive Officer, Founder

Richard Goold has a PhD in Pharmacology and has been in genomics since 1991.  He built the automation and bioinformatics arm of one of the first NIH-funded genome centers, the Human Genome Mapping Center at UCSF/Stanford.  He led the development of databases and systems to disseminate mapping data to GenBank and GDB.  Joining Incyte in 1995, he oversaw the gene mapping program, data analysis and the development of the commercial gene mapping database product, as well as Incyte's programs in full-length human gene sequencing, microbial genome sequencing, microbial microarrays and SNP discovery, including the associated data analysis pipelines and commercial database products.  Richard left Incyte to co-found Prospect Genomics, where he served as President until its successful merger with Structural Genomix.


Tod M Klingler PhD
Chief Scientific Officer, Founder

Tod Klingler has a PhD in Medical Information Sciences and Biochemistry from Stanford. As a computational biologist at Incyte, he helped launch the genomics product business and build an innovative research group.  He left Incyte in 2000 to co-found Prospect Genomics, where he led the development of a large-scale computational effort to explore protein-chemical interactions, and oversaw the integration of business and scientific strategies when the company was acquired by SGX.  As Vice President of Information Sciences for Synergenics, a biotechnology incubator, he set up and directed an informatics resource, providing computational services and strategic guidance to early stage companies.  Tod was Vice President of Information Sciences for molecular diagnostics company XDx, managing biostatistics, data analysis, software development and IT for the company's proprietary technology.  He has published scientific papers on the applications of genomic technology and is an inventor on more than 10 patents.


Randal W Scott, PhD
Chief Executive Officer, Invitae

Prior to co- founding InVitae, Randy served as Genomic Health’s Chief Executive Officer from 2000 until 2009 and Executive Chairman until 2012.  Under Randy’s leadership, Genomic Health developed and launched two revolutionary cancer diagnostics tests.  Prior to being one of the founders of Genomic Health, Randy was also a founder of Incyte Corporation, a genomic information company, and provider of integrated platforms of genomic technologies designed to aid in the understanding of the molecular basis of disease.  At Incyte, Randy served in various roles from 1991 through 2000, including Chairman of the Board, President and Chief Scientific Officer.  Randy holds a Bachelor of Science degree in Chemistry from Emporia State University and a PhD in Biochemistry from the University of Kansas.


Roy A. Whitfield
Former Chairman of the Board & Chief Executive Officer, Incyte

Roy A. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation, a company he co-founded in 1991.  He remains on the Board of Incyte and also serves as a director of Illumina, Inc., Nektar Therapeutics and several privately held companies.  Prior to Incyte, he held senior operating and business development positions with Technicon Instruments, a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc..  Roy received a B.S. in Mathematics from Oxford University and an M.B.A. from Stanford University.


Andre Bliznyuk
Partner, Runa Capital

Andre Bliznyuk is a partner at Runa Capital.  Until 2011, he headed the Russia/CIS Equity Capital Markets Group for Goldman Sachs and from 2006-2009 was with UBS Investment Bank, focusing on IPOs and other ECM transactions in Russia, Ukraine and Kazakhstan.  Prior to that, he was head of capital markets and investor relations at Sistema, a leading Russian conglomerate, managing debt and equity financing deals for Sistema, MTS, Comstar, Sistema Hals and Sitronics.  Andre graduated from MSU with a master's degree in Cross-Cultural Communications; followed this with a graduate course in Economics/Management.


Eric Schadt, PhD
Chief Science Officer, Pacific Biosciences
Director, Institute for Genomics & Multiscale Biology,
Mt Sinai School of Medicine

Eric Schadt is Director of the Institute for Genomics and Multiscale Biology and Chair of the Department of Genetics and Genomics Sciences at Mount Sinai School of Medicine.  He is also the Chief Science Officer at Pacific Biosciences and a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models.  He is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology.  Prior to 2009, he was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. and before that, he was a Senior Research Scientist at Roche Bioscience.  Eric received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics and his PhD in bio-mathematics from University of California, Los Angeles.



About Us

Station X is a startup developing a state-of-the-art web platform to revolutionize our understanding of human health & disease.  Our product, GenePool, is empowering scientists and medical professionals to make significant advances in medical research and healthcare with the promise to do so much more. We need you to help us achieve GenePool’s potential!

We are both founded and backed by an experienced team of genomics scientists.  Having just raised our second round of funding, we are now seeking to grow our team.  Our office is in downtown SF in a newly renovated space just a few blocks from Caltrain and the ballpark.  We offer competitive pay, stock options, health care benefits (health, dental and vision), a 401(k), and a public transit allowance. We have flexible work schedules and use Macs for development (but you can use whatever you like.) 

About You

You have an entrepreneurial spirit and a drive to create real-world applications that will change the way medicine is practiced.  You’re a self-starter that will thrive working as a part of an interdisciplinary team.

If you are interested in working with us and want to be considered for one of the openings below, please send a resume and cover letter to

Current Openings

Front-end Software Engineer

We are looking for a talented front-end engineer who likes to apply cutting edge technologies, builds usable modern web interfaces, writes quality code, enjoys working and collaborating with others, and is excited about playing a pivotal role in building a front end to present big and complex data to researchers and clinicians.

You are a front-end engineer with a fundamental understanding of JavaScript and have built applications from the ground up.  Experience with design is a bonus.  You also have an interest in developing software in a front-end stack that includes:
- Modular Javascript
- jQuery
- D3
- Backbone
- Gulp
- CSS3/Less 

(our backend stack includes Java, Hadoop, Redis, Postgres, and Python and we run on AWS)

You should have good product sense and be able to prototype and build features to match customer needs. Please be able to present examples of projects/websites that you have worked on.